OncoZenge

Following a successful feasibility study of LINK, we are positive about the appointment and selection of clinics in the Nordics and Germany, in line with the previously communicated plan and timeline.

OncoZenge is a Swedish research company developing BupiZenge™, a pain-relieving lozenge intended for the treatment of oral mucositis. The Company plans to conduct a European Phase 3 trial, which will form the basis for marketing authorisation of BupiZenge™ in Europe.

The focus remains on securing the final regulatory approvals for the investment agreement with Yangtian Pharma, with the aim of initiating the Phase 3 study of BupiZenge™.

Which includes Bahrain, Kuwait, Oman, Qatar, Saudi Arabia and the United Arab Emirates.

Regarding exclusive rights and a commercial partnership to introduce BupiZenge™ in Europe.

In summary, 2025 will be an intense year for OncoZenge, with shareholders having several milestones to look forward to, including the completion of the investment agreement with Yangtian and a finalized agreement with Molteni Farmaceutici.

The capital will be used to begin the Phase 3 study of BupiZenge™ and to strengthen OncoZenge's position in the global market.

The agreement secures financial resources to conduct the Company's European Phase 3 study.

OncoZenge will now work to explore partnerships with other stakeholders.

Additionally, Mogensen discusses the medical need for patients suffering from oral mucositis and shares his hopes for the future of BupiZenge™.

Her story underscores the urgent need for better pain relief solutions and highlights the often-overlooked challenges that patients face.

Impala Nordic produced the video on behalf of OncoZenge AB (publ).

Impala Nordic comments on the quarterly report.

This development underlines the potential for future product variants and confirms previous data. In parallel, the Company is exploring partnership opportunities in the Chinese market, with a focus on sales, clinical studies or licensing agreements.

At the same time, discussions are ongoing with potential partners for a Phase 3 study, where dialogue is being held with three different players. In February, OncoZenge also submitted a new patent application, which, if approved, could give BupiZenge™ market exclusivity until 2045.

They highlight how they have overcome past challenges and their focus on meeting patient needs heading into Phase 3. They also share insights on partnership plans and product positioning, and emphasize the company's goal of increasing transparency and trust with investors and stakeholders.

OncoZenge is currently working to secure PRIME status with the EMA, which could facilitate the regulatory process. With a drug candidate that has the potential to improve the quality of life for people with oral mucositis, OncoZenge faces exciting future opportunities.

During the interview, OncoZenge's strategies for getting the product to market, the collaboration with Ensysce Biosciences, the expansion into international markets, financial aspects and the goals for the company in 2024 are discussed.